Abstract Number: PB2099
Meeting: ISTH 2020 Congress
Background: The major complications of non-chronic myeloid leukemia myeloproliferative neoplasms (non CML-MPN) are arteriovenous thrombosis, hemorrhage and risk of leukemic transformation. Mutations in JAK2 are seen in this group of MPNs in varied proportions -95% of polycythemia vera (PV), 55% of essential thrombocythemia (ET) and 65% of primary myelofibrosis (PMF). Risk factors for thrombosis are older age, previous thrombotic event, increased hematocrit and spontaneous in vitro megakaryocyte colony formation. Effect of mutated JAK2 on risk of thrombotic events has not been studied in Southern India.
Aims: To study the association of thrombotic events with JAK2 mutation in patients of non CML-MPNs.
Methods: Institutional ethics committee approval was obtained. Single centre retrospective descriptive study of 73 cases of bone marrow confirmed MPNs (from June 2013 to July 2018) was conducted. Age, gender, complete blood counts at diagnosis, occurrence of thrombotic events and JAK2 mutation status by real time polymerase chain reaction were recorded at a minimum follow-up period of 6 months. Continuous data was expressed in mean + SD. Association between CBC, mutated JAK2 and thrombosis was studied by Fisher exact test.
Results: Forty cases were included the study as remaining 33 cases did not undergo testing for JAK2 mutation. Figure 1 depicts the case distribution. Summary of association of thrombosis with age, gender and CBC parameters are given in table 1. Thrombosis occurred in 67.6% of MPN with JAK2 mutation (p value: 0.03).
Conclusions: Previous studies imply that JAK-2 mutational status might represent a novel disease-associated risk factor that should ideally be incorporate into risk stratification risk factor. However, we did not find significant association of thrombosis with JAK2 mutation. However, high hematocrit and total WBC count particularly in PV is significantly associated with risk of thrombosis.
|Polycythemia vera||Essential thrombocythemia||Primary myelofibrosis||p value|
|Age in years||55.10 (11.47)||56.71 (14.13)||66.00 (7.07)||0.453|
|Males||21 (70.0)||7 ( 87.5)||0||0.127|
|Females||9 (30.0)||1 ( 12.5)||2 (100.0)|
|Hemoglobin/dL||20.51 (10.86)||20.73 (11.09)||36.70 (22.20)||0.161|
|Hematocrit||16.03 (2.71)||11.61 (3.36)||9.75 (0.35)||<0.001|
|Mean platelet volume in fL||8.37 (0.81)||8.89 (1.20)||6.80 (0.57)||0.02|
|Platelet count X1000/µL||590.27 (335.43)||624.38 (316.77)||78.05 (101.75)||0.103|
|WBC count X1000/µL||7.10 (1.53)||4.58 (0.92)||3.26 (0.16)||<0.001|
[Table 1: Association of thrombosis with age, gender and CBC parameters]
To cite this abstract in AMA style:Koulmane Laxminarayana SL, Bhattacharya R. JAK2 Mutation: A Predictor of Thrombotic Events in Myeloproliferative Neoplasia? [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/jak2-mutation-a-predictor-of-thrombotic-events-in-myeloproliferative-neoplasia/. Accessed December 6, 2021.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/jak2-mutation-a-predictor-of-thrombotic-events-in-myeloproliferative-neoplasia/